389 related articles for article (PubMed ID: 29861296)
1. The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma.
McBride MJ; Pulice JL; Beird HC; Ingram DR; D'Avino AR; Shern JF; Charville GW; Hornick JL; Nakayama RT; Garcia-Rivera EM; Araujo DM; Wang WL; Tsai JW; Yeagley M; Wagner AJ; Futreal PA; Khan J; Lazar AJ; Kadoch C
Cancer Cell; 2018 Jun; 33(6):1128-1141.e7. PubMed ID: 29861296
[TBL] [Abstract][Full Text] [Related]
2. A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction.
Li J; Mulvihill TS; Li L; Barrott JJ; Nelson ML; Wagner L; Lock IC; Pozner A; Lambert SL; Ozenberger BB; Ward MB; Grossmann AH; Liu T; Banito A; Cairns BR; Jones KB
Cancer Discov; 2021 Oct; 11(10):2620-2637. PubMed ID: 34078620
[TBL] [Abstract][Full Text] [Related]
3. Reversible disruption of mSWI/SNF (BAF) complexes by the SS18-SSX oncogenic fusion in synovial sarcoma.
Kadoch C; Crabtree GR
Cell; 2013 Mar; 153(1):71-85. PubMed ID: 23540691
[TBL] [Abstract][Full Text] [Related]
4. SS18-SSX, the Oncogenic Fusion Protein in Synovial Sarcoma, Is a Cellular Context-Dependent Epigenetic Modifier.
Tamaki S; Fukuta M; Sekiguchi K; Jin Y; Nagata S; Hayakawa K; Hineno S; Okamoto T; Watanabe M; Woltjen K; Ikeya M; Kato T; Toguchida J
PLoS One; 2015; 10(11):e0142991. PubMed ID: 26571495
[TBL] [Abstract][Full Text] [Related]
5. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models of Synovial Sarcoma.
Kawano S; Grassian AR; Tsuda M; Knutson SK; Warholic NM; Kuznetsov G; Xu S; Xiao Y; Pollock RM; Smith JS; Kuntz KK; Ribich S; Minoshima Y; Matsui J; Copeland RA; Tanaka S; Keilhack H
PLoS One; 2016; 11(7):e0158888. PubMed ID: 27391784
[TBL] [Abstract][Full Text] [Related]
6. Aberrant gene activation in synovial sarcoma relies on SSX specificity and increased PRC1.1 stability.
Benabdallah NS; Dalal V; Scott RW; Marcous F; Sotiriou A; Kommoss FKF; Pejkovska A; Gaspar L; Wagner L; Sánchez-Rivera FJ; Ta M; Thornton S; Nielsen TO; Underhill TM; Banito A
Nat Struct Mol Biol; 2023 Nov; 30(11):1640-1652. PubMed ID: 37735617
[TBL] [Abstract][Full Text] [Related]
7. The chromatin landscape of primary synovial sarcoma organoids is linked to specific epigenetic mechanisms and dependencies.
Boulay G; Cironi L; Garcia SP; Rengarajan S; Xing YH; Lee L; Awad ME; Naigles B; Iyer S; Broye LC; Keskin T; Cauderay A; Fusco C; Letovanec I; Chebib I; Nielsen PG; Tercier S; Cherix S; Nguyen-Ngoc T; Cote G; Choy E; Provero P; Suvà ML; Rivera MN; Stamenkovic I; Riggi N
Life Sci Alliance; 2021 Feb; 4(2):. PubMed ID: 33361335
[TBL] [Abstract][Full Text] [Related]
8. Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics.
Su L; Sampaio AV; Jones KB; Pacheco M; Goytain A; Lin S; Poulin N; Yi L; Rossi FM; Kast J; Capecchi MR; Underhill TM; Nielsen TO
Cancer Cell; 2012 Mar; 21(3):333-47. PubMed ID: 22439931
[TBL] [Abstract][Full Text] [Related]
9. Synovial Sarcoma: A Complex Disease with Multifaceted Signaling and Epigenetic Landscapes.
El Beaino M; Rassy E; Hadid B; Araujo DM; Pavlidis N; Lin PP
Curr Oncol Rep; 2020 Oct; 22(12):124. PubMed ID: 33025259
[TBL] [Abstract][Full Text] [Related]
10. Interdependence of SS18-SSX-driven YAP1 and β-Catenin Activation in Synovial Sarcoma.
Isfort I; Berthold R; Heinst L; Wardelmann E; Larsson O; Trautmann M; Hartmann W
Mol Cancer Res; 2023 Jun; 21(6):535-547. PubMed ID: 36920288
[TBL] [Abstract][Full Text] [Related]
11. Expanding the Use of an SS18-SSX Antibody for Molecular Assays in Synovial Sarcoma.
Raquib AR; Hofvander J; Ta M; Nielsen TO
Appl Immunohistochem Mol Morphol; 2022 Sep; 30(8):531-539. PubMed ID: 35880992
[TBL] [Abstract][Full Text] [Related]
12. The SS18-SSX Oncoprotein Hijacks KDM2B-PRC1.1 to Drive Synovial Sarcoma.
Banito A; Li X; Laporte AN; Roe JS; Sanchez-Vega F; Huang CH; Dancsok AR; Hatzi K; Chen CC; Tschaharganeh DF; Chandwani R; Tasdemir N; Jones KB; Capecchi MR; Vakoc CR; Schultz N; Ladanyi M; Nielsen TO; Lowe SW
Cancer Cell; 2018 Mar; 33(3):527-541.e8. PubMed ID: 29502955
[TBL] [Abstract][Full Text] [Related]
13. Phase transition and remodeling complex assembly are important for SS18-SSX oncogenic activity in synovial sarcomas.
Cheng Y; Shen Z; Gao Y; Chen F; Xu H; Mo Q; Chu X; Peng CL; McKenzie TT; Palacios BE; Hu J; Zhou H; Long J
Nat Commun; 2022 May; 13(1):2724. PubMed ID: 35585082
[TBL] [Abstract][Full Text] [Related]
14. Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.
Carmody Soni EE; Schlottman S; Erkizan HV; Uren A; Toretsky JA
Clin Orthop Relat Res; 2014 Mar; 472(3):874-82. PubMed ID: 23716114
[TBL] [Abstract][Full Text] [Related]
15. Frequent TRPS1 expression in synovial sarcoma is associated with SS18-SSX fusion oncoprotein activity.
Cloutier JM; Ingram DR; Wani K; Lazar AJ; Wang WL
Hum Pathol; 2022 Dec; 130():88-94. PubMed ID: 36162599
[TBL] [Abstract][Full Text] [Related]
16. Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.
Yoneda Y; Ito S; Kunisada T; Morimoto Y; Kanzaki H; Yoshida A; Shimizu K; Ozaki T; Ouchida M
PLoS One; 2013; 8(10):e77564. PubMed ID: 24130893
[TBL] [Abstract][Full Text] [Related]
17. Synovial sarcoma is a gateway to the role of chromatin remodeling in cancer.
Zöllner SK; Rössig C; Toretsky JA
Cancer Metastasis Rev; 2015 Sep; 34(3):417-28. PubMed ID: 26277104
[TBL] [Abstract][Full Text] [Related]
18. Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.
Lubieniecka JM; de Bruijn DR; Su L; van Dijk AH; Subramanian S; van de Rijn M; Poulin N; van Kessel AG; Nielsen TO
Cancer Res; 2008 Jun; 68(11):4303-10. PubMed ID: 18519690
[TBL] [Abstract][Full Text] [Related]
19. Targeting of SUMOylation leads to cBAF complex stabilization and disruption of the SS18::SSX transcriptome in Synovial Sarcoma.
Floros KV; Fairchild CK; Li J; Zhang K; Roberts JL; Kurupi R; Hu B; Kraskauskiene V; Hosseini N; Shen S; Inge MM; Smith-Fry K; Li L; Sotiriou A; Dalton KM; Jose A; Abdelfadiel EI; Xing Y; Hill RD; Slaughter JM; Shende M; Lorenz MR; Hinojosa MR; Belvin BR; Lai Z; Boikos SA; Stamatouli AM; Lewis JP; Manjili MH; Valerie K; Li R; Banito A; Poklepovic A; Koblinski JE; Siggers T; Dozmorov MG; Jones KB; Radhakrishnan SK; Faber AC
bioRxiv; 2024 Apr; ():. PubMed ID: 38712286
[TBL] [Abstract][Full Text] [Related]
20. Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma.
Brien GL; Remillard D; Shi J; Hemming ML; Chabon J; Wynne K; Dillon ET; Cagney G; Van Mierlo G; Baltissen MP; Vermeulen M; Qi J; Fröhling S; Gray NS; Bradner JE; Vakoc CR; Armstrong SA
Elife; 2018 Nov; 7():. PubMed ID: 30431433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
